Cargando…

Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer

The immune checkpoint inhibitor atezolizumab is approved for PD-L1-positive triple-negative breast cancer (TNBC). However, no activity of atezolizumab in PD-L1-negative TNBC has been reported to date. Here, we present the case study of a woman with TNBC with low tumor infiltrating lymphocytes and PD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brasó-Maristany, Fara, Sansó, Miriam, Chic, Nuria, Martínez, Débora, González-Farré, Blanca, Sanfeliu, Esther, Ghiglione, Lucio, Carcelero, Esther, Garcia-Corbacho, Javier, Sánchez, Marcelo, Soy, Dolors, Jares, Pedro, Peg, Vicente, Saura, Cristina, Muñoz, Montserrat, Prat, Aleix, Vivancos, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489403/ https://www.ncbi.nlm.nih.gov/pubmed/34616675 http://dx.doi.org/10.3389/fonc.2021.710596

Ejemplares similares

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
por: Schettini, Francesco, et al.
Publicado: (2022)

Gene expression profiles of breast cancer metastasis according to organ site
por: Brasó‐Maristany, Fara, et al.
Publicado: (2021)

A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes
por: Schettini, Francesco, et al.
Publicado: (2022)

Frequency and spectrum of PIK3CA somatic mutations in breast cancer
por: Martínez-Sáez, Olga, et al.
Publicado: (2020)

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy
por: Chic, Nuria, et al.
Publicado: (2021)

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
por: Prat, Aleix, et al.
Publicado: (2022)

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
por: Prat, Aleix, et al.
Publicado: (2021)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2023)

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
por: Martínez-Sáez, Olga, et al.
Publicado: (2021)

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
por: Prat, Aleix, et al.
Publicado: (2023)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
por: Guarneri, Valentina, et al.
Publicado: (2022)

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials
por: Fernandez-Martinez, Aranzazu, et al.
Publicado: (2023)

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
por: Pascual, Tomás, et al.
Publicado: (2019)

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
por: Phua, Lee Cheng, et al.
Publicado: (2020)

Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease
por: Isola, Ignacio, et al.
Publicado: (2021)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Brasó-Maristany, Fara, et al.
Publicado: (2020)

Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer
por: Patel, Nirmesh, et al.
Publicado: (2018)

A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab
por: Sawatari, Kosuke, et al.
Publicado: (2022)

Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancer
por: Schettini, F., et al.
Publicado: (2021)

Two Cases of Atezolizumab-Induced Hypophysitis
por: Kanie, Keitaro, et al.
Publicado: (2017)

ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer
por: Schmid, Peter
Publicado: (2018)

Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer
por: Wu, Bin, et al.
Publicado: (2020)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2021)

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
por: Emens, Leisha A, et al.
Publicado: (2021)

Collagenous colitis and atezolizumab therapy: an atypical case
por: Gallo, Antonella, et al.
Publicado: (2020)

Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling
por: Cuenca-López, María D, et al.
Publicado: (2014)

The surge of HBsAb level in a HBsAg-negative ES-SCLC patient after anlotinib plus atezolizumab treatment: A case report
por: Chen, Gangjun, et al.
Publicado: (2023)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
por: Franzoi, Maria Alice, et al.
Publicado: (2020)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety
por: Sharmni Vishnu, K., et al.
Publicado: (2022)

A Rare Case Presentation of Vitiligo Associated With Atezolizumab
por: Nwanwene, Kemnasom, et al.
Publicado: (2023)

Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8
por: Jerusalem, Guy, et al.
Publicado: (2023)

Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response
por: Ciriaco, Nikaoly, et al.
Publicado: (2022)

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
por: Liu, Xiaoyan, et al.
Publicado: (2021)

Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer
por: Barrios, Carlos H., et al.
Publicado: (2022)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Atezolizumab-induced encephalitis in a patient with metastatic breast cancer: a case report and review of neurological adverse events associated with checkpoint inhibitors
por: Nader, Rita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e1lg68d21vt018q9pj0ru974q8